• E&INVESTMENT and related funds reduced their Epi Biotech shareholding and voting rights to 3.14% from 10.25% as of November 12, 2026.
• Holdings fell by 209,324 shares to 99,972 through market sales and in-kind distributions to fund members following liquidation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Epi Biotech Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261112000747), on November 13, 2026, and is solely responsible for the information contained therein.